Corbus Pharmaceutica (CRBP) 2.1200 $CRBP
Corbus Plans Multiple Clinical Trials With Resunab In Orphan Indications
Jason Napodano, CFA - at Seeking Alpha - Wed Feb 11, 2:10PM CST
Corbus Pharmaceuticals to Present at the Leerink Global Healthcare Conference on February 11, 2015
Marketwired - Wed Feb 11, 6:35AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"
, an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that it is presenting at the 2015 Leerink Global Healthcare Conference on February 11, 2015, at 3:05 p.m. EST the Waldorf Astoria in New York, New York.
Corbus Pharmaceuticals Reports 2014 Financial Results and Provides 2015 Business Update
Marketwired - Tue Feb 10, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company" , an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today its financial results for the year ended December 31, 2014.
Corbus Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015
Marketwired - Mon Feb 02, 7:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company" , an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that it will be presenting at the 17th Annual BIO CEO & Investor Conference being held February 9-10, 2015, at the Waldorf Astoria in New York, New York.
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
Marketwired - Wed Jan 07, 7:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company" , an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that its Chief Executive Officer, Yuval Cohen, Ph.D., will be presenting at two upcoming investor conferences in January, 2015.
Corbus Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference on December 10, 2014
Marketwired - Wed Dec 03, 7:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company" , an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today it will be presenting at the Oppenheimer & Co. 25th Annual HealthCare Conference being held December 10-11, 2014, at the Crowne Plaza Hotel in New York, New York.
Eight Companies Webcast Live to Investors, December 4th at VirtualInvestorConferences.com
CNW Group - Tue Dec 02, 7:29AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
SMLR: 4.54 (+0.20), ONVO: 6.34 (+0.07), CYTX: 0.47 (unch), IAG: 2.23 (-0.08)
Corbus Pharmaceuticals to Present at VirtualInvestorConferences.com Online Event on December 4, 2014
PR Newswire - Mon Dec 01, 8:42AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company" , an emerging growth drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will be presenting at VirtualInvestorConferences.com, a live and interactive online event, on Thursday, December 4, 2014 at 11:30 a.m. Eastern Standard Time.
Fort Point Angels Scores First Successful "Exit"
PR Newswire - Mon Dec 01, 8:37AM CST
Fort Point Angels LLC, an angel investment fund that makes seed and early-stage investments in growth-industry companies, announced its first successful "exit" with the initial public offering of Corbus Pharmaceuticals Holdings Inc., of Norwood, MA.
Corbus Pharmaceuticals reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:18AM CST
Corbus Pharmaceuticals Reports 2014 Third Quarter Results and Business Update
Marketwired - Thu Nov 13, 5:01AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company" , an emerging growth drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today its financial results for the third quarter ended September 30, 2014. The Company also provided an update on its corporate progress and anticipated near-term clinical development milestones for Resunab(TM), its novel synthetic oral specialized pro-resolving mediator drug with unique anti-inflammatory and anti-fibrotic activity.
Corbus Pharmaceuticals Commences Trading on OTCQB under Ticker Symbol CRBP
Marketwired - Tue Oct 28, 6:05AM CDT
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP), an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory diseases, announced today that shares of the Company's common stock have initiated trading on the Over-the-Counter Markets (OTCQB) under the ticker symbol "CRBP."
Corbus Plans Multiple Clinical Trials With Resunab In Orphan Indications
Jason Napodano, CFA - at Seeking Alpha - Wed Feb 11, 2:10PM CST
Corbus Pharmaceuticals to Present at the Leerink Global Healthcare Conference on February 11, 2015
Marketwired - Wed Feb 11, 6:35AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"
, an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that it is presenting at the 2015 Leerink Global Healthcare Conference on February 11, 2015, at 3:05 p.m. EST the Waldorf Astoria in New York, New York. Corbus Pharmaceuticals Reports 2014 Financial Results and Provides 2015 Business Update
Marketwired - Tue Feb 10, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"
, an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today its financial results for the year ended December 31, 2014. Corbus Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015
Marketwired - Mon Feb 02, 7:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"
, an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that it will be presenting at the 17th Annual BIO CEO & Investor Conference being held February 9-10, 2015, at the Waldorf Astoria in New York, New York. Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
Marketwired - Wed Jan 07, 7:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"
, an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that its Chief Executive Officer, Yuval Cohen, Ph.D., will be presenting at two upcoming investor conferences in January, 2015. Corbus Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference on December 10, 2014
Marketwired - Wed Dec 03, 7:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"
, an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today it will be presenting at the Oppenheimer & Co. 25th Annual HealthCare Conference being held December 10-11, 2014, at the Crowne Plaza Hotel in New York, New York. Eight Companies Webcast Live to Investors, December 4th at VirtualInvestorConferences.com
CNW Group - Tue Dec 02, 7:29AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
SMLR: 4.54 (+0.20), ONVO: 6.34 (+0.07), CYTX: 0.47 (unch), IAG: 2.23 (-0.08)
Corbus Pharmaceuticals to Present at VirtualInvestorConferences.com Online Event on December 4, 2014
PR Newswire - Mon Dec 01, 8:42AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"
, an emerging growth drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will be presenting at VirtualInvestorConferences.com, a live and interactive online event, on Thursday, December 4, 2014 at 11:30 a.m. Eastern Standard Time. Fort Point Angels Scores First Successful "Exit"
PR Newswire - Mon Dec 01, 8:37AM CST
Fort Point Angels LLC, an angel investment fund that makes seed and early-stage investments in growth-industry companies, announced its first successful "exit" with the initial public offering of Corbus Pharmaceuticals Holdings Inc., of Norwood, MA.
Corbus Pharmaceuticals reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:18AM CST
Corbus Pharmaceuticals Reports 2014 Third Quarter Results and Business Update
Marketwired - Thu Nov 13, 5:01AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"
, an emerging growth drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today its financial results for the third quarter ended September 30, 2014. The Company also provided an update on its corporate progress and anticipated near-term clinical development milestones for Resunab(TM), its novel synthetic oral specialized pro-resolving mediator drug with unique anti-inflammatory and anti-fibrotic activity. Corbus Pharmaceuticals Commences Trading on OTCQB under Ticker Symbol CRBP
Marketwired - Tue Oct 28, 6:05AM CDT
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP), an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory diseases, announced today that shares of the Company's common stock have initiated trading on the Over-the-Counter Markets (OTCQB) under the ticker symbol "CRBP."
